View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit™.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Array BioPharma Inc., Incyte, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc., and Reata Pharmaceuticals.


Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® PER Pulse™ Recap

PER Pulse Recap

PER Pulse™ Recap


Management of BRAF-Mutant Melanoma

Featuring key melanoma experts Michael Postow, MD, and Jeffrey Weber, MD, PhD, this first of 3 PER Pulse™ Recaps from Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® summarizes expert perspectives on a clinical vignette of a patient with metastatic melanoma and a BRAF-V600E mutation:

  • The clinical vignette involves a patient with symptomatic, BRAF-V600E mutation-positive melanoma. Although immunotherapy can be a frontline therapeutic option, expert recommendation for initial therapy is to pursue combination BRAF/MEK inhibition for rapid antitumor activity and symptom palliation.
  • Two combinations of a BRAF inhibitor and a MEK inhibitor are available: dabrafenib/trametinib and vemurafenib/cobimetinib. Both combinations have shown improved progression-free survival (PFS) and overall survival compared with single-agent BRAF inhibition. A third combination, encorafenib/binimetinib, has also demonstrated a PFS benefit over a BRAF inhibitor alone.
  • Combinations of immunotherapy with BRAF/MEK inhibitors are being studied. For example, phase I data have shown an overall response rate of 83% with the combination of atezolizumab with vemurafenib/cobimetinib in patients with BRAF-mutant melanoma, and the triplet is currently in phase III investigation.

For additional commentary about this topic and others, visit www.gotoper.com to access downloadable slides from the 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.



2 of 3
PER Pulse™ Recap

Management of BRAF Wild-Type Melanoma

Featuring key melanoma experts Omid Hamid, MD, and Michael Postow, MD, this second of 3 PER Pulse™ Recaps from Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® summarizes expert perspectives on a clinical vignette of a patient with metastatic melanoma and wild-type BRAF genes:

  • The clinical vignette involved a patient with metastatic BRAF wild-type melanoma. The expert recommendation is immunotherapy since BRAF inhibition is not indicated in patients with wild-type BRAF genes. For immunotherapy, inhibition of the PD-1/PD-L1 axis is preferable, as this approach has demonstrated superiority to single-agent CTLA-4 inhibition.
  • Currently, there are 2 anti–PD-1 antibodies available as single agents: pembrolizumab and nivolumab. In the KEYNOTE-006 trial, pembrolizumab demonstrated superior overall survival (OS) and progression-free survival (PFS) compared with ipilimumab, while nivolumab yielded superior OS and PFS compared with dacarbazine in the CheckMate 066 trial.
  • Initial results of the first-line CheckMate 067 trial showed that PFS was superior with nivolumab/ipilimumab or single-agent nivolumab compared with ipilimumab; updated results also demonstrated superior OS with both nivolumab-containing regimens.
  • Investigational approaches in patients with advanced BRAF wild-type melanoma include the addition of indoleamine 2, 3-dioxygenase inhibitors or MEK inhibitors to immune checkpoint inhibitors. Both approaches are in phase III investigation.

For additional commentary about this topic and others, visit www.gotoper.com to access downloadable slides from the 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.


3 of 3
PER Pulse™ Recap

Advances in Merkel Cell Carcinoma

Featuring key experts in cutaneous malignancies Jeffrey Weber, MD, PhD, and Omid Hamid, MD, this third of 3 PER Pulse™ Recaps from Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® summarizes the development of immunotherapy in patients with Merkel cell carcinoma (MCC):

  • In March 2017, the anti–PD-L1 antibody avelumab received accelerated approval from the FDA based on phase II data from the JAVELIN Merkel 200 trial. This approval applies to patients ≥12 years of age with metastatic MCC. In the JAVELIN trial, avelumab yielded responses in 32% of patients, including complete responses (CRs) in 9% of patients.
  • Pembrolizumab has also demonstrated activity in MCC. In a phase II trial enrolling patients with no prior systemic therapy, pembrolizumab yielded an overall response rate of 56%, including CRs in 16% of patients,. Patients had a median progression-free survival of 9 months.

For additional commentary about this topic and others, visit www.gotoper.com to access downloadable slides from the 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.





Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By